MaxCyte, Inc. (NASDAQ:MXCT) EVP Sells $54,529.93 in Stock

MaxCyte, Inc. (NASDAQ:MXCT) EVP Thomas M. Ross sold 13,531 shares of the company’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $4.03, for a total transaction of $54,529.93. Following the completion of the transaction, the executive vice president now owns 25,000 shares in the company, valued at $100,750. The sale was disclosed in a filing with the SEC, which is available through this link.

MaxCyte Price Performance

MaxCyte stock traded down $0.07 during trading hours on Wednesday, hitting $4.11. 180,076 shares of the stock traded hands, compared to its average volume of 609,550. The firm’s 50 day moving average price is $4.40 and its 200-day moving average price is $4.47. The stock has a market capitalization of $430.81 million, a price-to-earnings ratio of -11.94 and a beta of 1.41. MaxCyte, Inc. has a 1 year low of $2.45 and a 1 year high of $5.55.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.05. The company had revenue of $11.34 million for the quarter, compared to the consensus estimate of $7.75 million. MaxCyte had a negative net margin of 83.00% and a negative return on equity of 15.68%. Research analysts forecast that MaxCyte, Inc. will post -0.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on MXCT shares. BTIG Research dropped their price target on MaxCyte from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, March 13th. Stephens reiterated an “overweight” rating and issued a $11.00 price target on shares of MaxCyte in a research note on Tuesday, April 23rd. Finally, William Blair restated an “outperform” rating on shares of MaxCyte in a research note on Wednesday, March 13th.

Institutional Investors Weigh In On MaxCyte

Several hedge funds have recently added to or reduced their stakes in the business. Cadian Capital Management LP purchased a new stake in shares of MaxCyte in the fourth quarter worth about $26,531,000. Vanguard Group Inc. increased its holdings in shares of MaxCyte by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 5,347,112 shares of the company’s stock valued at $22,404,000 after purchasing an additional 65,004 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of MaxCyte by 29.9% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 2,537,114 shares of the company’s stock valued at $11,924,000 after purchasing an additional 584,372 shares during the period. River Global Investors LLP boosted its holdings in MaxCyte by 24.4% during the first quarter. River Global Investors LLP now owns 1,888,642 shares of the company’s stock worth $7,973,000 after buying an additional 369,996 shares in the last quarter. Finally, Mudita Advisors LLP grew its position in MaxCyte by 35.3% during the fourth quarter. Mudita Advisors LLP now owns 1,881,349 shares of the company’s stock valued at $8,842,000 after buying an additional 490,491 shares during the period. 68.81% of the stock is owned by hedge funds and other institutional investors.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.